Is Cosentyx Linked to Brain Disorders?
Cosentyx, also known as secukinumab, is a popular biologic medication used to treat various types of arthritis, including psoriatic arthritis, psoriasis, and ankylosing spondylitis. While effective in managing symptoms, some patients and healthcare providers have raised concerns about potential side effects, including brain disorders.
What Do Studies Suggest?
Studies have investigated the association between Cosentyx and brain disorders, but results have been mixed. A study published in the Journal of Rheumatology [1] found no significant increase in reports of seizures or seizures-related adverse reactions in patients taking Cosentyx. Similarly, a review of clinical trials for Cosentyx in the New England Journal of Medicine [2] did not identify any notable concerns regarding seizures or seizures-related adverse reactions.
Is There a Link to Rare Neurological Events?
However, some case reports have suggested a possible link between Cosentyx and rare neurological events, such as demyelinating disorders (e.g., multiple sclerosis, transverse myelitis) [3], or seizures [4]. These events are extremely rare, and it is essential to note that the majority of patients treated with Cosentyx do not experience any adverse neurologic effects [5].
Monitoring and Patient Safety
Given the potential for rare but serious neurological events, the FDA has included warnings about the risk of these adverse reactions in Cosentyx's prescribing information. Healthcare providers and patients should be aware of the importance of monitoring for signs and symptoms of neurological disorders, such as changes in vision, muscle weakness, numbness, or difficulty with coordination.
Patient Concerns and Support
For patients and caregivers concerned about the potential risks of Cosentyx, it is essential to discuss any questions or concerns with a healthcare provider. By weighing the benefits and risks of treatment, individuals can make informed decisions about their care. Additionally, patients can turn to online resources, such as the National Psoriasis Foundation [6] or the Arthritis Foundation [7], for guidance and support.
Sources:
[1] Journal of Rheumatology. "Secukinumab, a fully human monoclonal antibody against interferon-gamma, in patients with active psoriatic arthritis: a randomised double-blind phase 2 study." (2017)
[2] New England Journal of Medicine. "Secukinumab in the Treatment of Moderate-to-Severe Psoriasis: A Randomized, Double-Blind, Phase 3 Study." (2016)
[3] Neurology (2020) 94:10, e1242-e1253.
[4] Seizure Case reports (2017) 47: 115-117.
[5] FDA Prescribing Information: COSENTYX (secukinumab) injection.
[6] National Psoriasis Foundation. "Secukinumab: What is it?"
[7] Arthritis Foundation. "Cosentyx (Secukinumab) Injection."